Company Profile
Aprea Therapeutics Stock Price, News & Catalysts
- Ticker:
- APRE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.69 USD (+1.49%)
Close
Last updated: August 17, 2026
9.46M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, APRE closed up 1.49% at $0.6900. No new same-company headline was identified in the current news window.
Company overview
DNA Damage Response Oncology
Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells.
APR-1051
APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for advanced solid tumors. The program is designed to improve the therapeutic window relative to earlier WEE1 inhibitors.
Biomarker-Directed Expansion
Aprea is expanding APR-1051 in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. It also plans combination work in HPV-positive head-and-neck cancer and colorectal cancer.
ATRN-119
ATRN-119 is a macrocyclic ATR inhibitor that has completed Phase 1 dose escalation. Aprea is evaluating potential combination development with immunotherapy, chemotherapy, antibody-drug conjugates, and radiation.
Future catalysts
- Clinical data update from the Phase 1 ACESOT-1051 study of APR-1051 at a medical meeting in the fourth quarter of 2026.
- Potential entry of Aprea's macrocyclic DYRK1A/B inhibitor into IND-enabling studies in the fourth quarter of 2026.
- Completion of APR-1051 dose escalation and backfill expansion in the second quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aprea Therapeutics (APRE)?
Aprea Therapeutics (APRE) most recently closed at 0.69 USD, a +1.49% move versus the previous session.
What is the market cap of Aprea Therapeutics (APRE)?
Aprea Therapeutics currently has a market capitalization of 9.46M USD on BioPharmSignal.
What does Aprea Therapeutics do?
DNA Damage Response Oncology Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells. APR-1051 APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for advanced solid tumors. The...
On which exchange is APRE stock listed?
Aprea Therapeutics (APRE) is associated with NASDAQ, United States, Biopharma.
What is APR-1051?
Clinical data update from the Phase 1 ACESOT-1051 study of APR-1051 at a medical meeting in the fourth quarter of 2026.
Which conditions is Aprea Therapeutics targeting with APR-1051?
Aprea Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Aprea Therapeutics describe recent progress with APR-1051?
Clinical data update from the Phase 1 ACESOT-1051 study of APR-1051 at a medical meeting in the fourth quarter of 2026.
What is ACESOT-1051?
APR-1051 APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for advanced solid tumors.